A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

被引：0
|
作者：
Crombie, Jennifer L. [1 ]
Ryan, Christine E. [2 ]
Ren, Yue [2 ]
Tyekucheva, Svitlana [3 ]
Carey, Celeste [4 ]
Zou, Aaron [4 ]
Normilus, Samantha [4 ]
Montegaard, Josie [4 ]
Soumerai, Jacob D. [5 ]
Bhandari, Shruti [6 ]
Arnason, Jon E. [7 ]
Alencar, Alvaro J. [8 ]
Kim, Austin I. [9 ]
Parry, Erin M. [2 ]
Armand, Philippe [2 ]
Fisher, David C. [2 ]
Brown, Jennifer R. [10 ]
Davids, Matthew S. [11 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Northern Light Canc Care, Dept Hematol & Oncol, Brewer, ME USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Div Hematol, Miami Beach, FL USA
[9] Dana Farber Canc Inst, Dept Med Oncol, Newton Ctr, MA USA
[10] Dana Farber Canc Inst, Dept Med Oncol, Newton, MA USA
[11] Dana Farber Canc Inst Inc, Dept Med Oncol, Boston, MA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-199234
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4628 / 4629
页数：2
相关论文
共 50 条
  • [31] Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)
    Sun, Clare C.
    Nierman, Pia
    Ahn, Inhye E.
    Valdez, Janet
    Lotter, Jennifer
    Soto, Susan
    Herman, Sarah E. M.
    Covey, Todd
    Hamdy, Ahmed
    Izumi, Raquel
    Liu, Dongmei
    Patel, Priti
    Wiestner, Adrian
    BLOOD, 2018, 132
  • [32] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [33] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [34] ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan Mary
    Qiu, Lugui
    Paik, Jason C.
    Hilger, James D.
    Huang, Jane
    Tam, Constantine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL)
    Tian, Shulan
    Wang, Hanyin
    Call, Timothy G.
    Klee, Eric W.
    Liu, Minetta C.
    Jessen, Erik
    Parikh, Sameer A.
    Wang, Yucai
    Kenderian, Saad S.
    Leis, Jose F.
    Shi, Min
    Muchtar, Eli
    Van Dyke, Daniel L.
    Koehler, Amber B.
    Kay, Neil E.
    Slager, Susan L.
    Braggio, Esteban
    Yan, Huihuang
    Ding, Wei
    BLOOD, 2020, 136
  • [36] Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Hebart, Holger
    Ghia, Paolo
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Patel, Priti
    Quah, Cheng
    Liang, Wei
    Lee, Jae Hoon
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 128 - 129
  • [37] ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abe
    Avery, E. J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2020, 61 : 235 - 237
  • [38] Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study
    Jones, Jeffrey Alan
    Geyer, Susan
    Andritsos, Leslie A.
    Awan, Farrukh
    Flynn, Joseph M.
    Maddocks, Kami J.
    Bingman, Anissa
    Johnson, Amy J.
    Heerema, Nyla A.
    Brookfield, Cathy
    Byrd, John C.
    Grever, Michael R.
    BLOOD, 2014, 124 (21)
  • [39] UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.
    Piris-Villaespesa, M.
    Chavez, J.
    Dalia, S.
    Veliz, M.
    Lancet, Jeffrey
    Bello, C.
    Turba, E.
    Shah, B.
    Komrokji, R.
    Sokol, L.
    Locke, F.
    Kharfan-Dabaja, M.
    Sotomayor, E.
    Pinilla-Ibarz, J.
    HAEMATOLOGICA, 2013, 98 : 46 - 46
  • [40] MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Seymour, John F.
    Kipps, Thomas J.
    Eichhorst, Barbara
    Hillmen, Peter
    D'Rozario, James
    Assouline, Sarit
    Owen, Carolyn
    Robak, Tadeusz
    de la Serna, Javier
    Jaeger, Ulrich
    Cartron, Guillaume
    Montillo, Marco
    Lamanna, Nicole
    Verdugo, Maria E.
    Punnoose, Elizabeth A.
    Jiang, Yanwen
    Wang, Jue
    Boyer, Michelle
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kater, Arnon P.
    BLOOD, 2018, 132
12345